RSLS Nasdaq

ReShape Lifesciences Inc.

RSLS | $0.1707 15K

(0.0% 1d) (-7.0% 1m) (-94.4% 1y) (0.0% 2d) (0.0% 3d) (-2.7% 7d) (81.67% volume)
Earnings Calendar: 2023-11-13
Market Cap: $ 4,004,125
https://www.obalon.com
Sec Filling | Patents | 2 employees

(United States) Obalon Therapeutics, Inc. is a San Diego-based company focused on developing and commercializing novel technologies for weight loss.

add to watch list Paper trade email alert is off

Press-releases

ReShape Lifesciences® Receives Notice of Allowance for Additional U.S. Patent Related to an Intragastric Balloon System
Published: 2024-03-28 (Crawled : 12:30) - globenewswire.com
RSLS | $0.1707 15K

Manufacturing

| -11.7% | O: 5.08% H: 3.99% C: -3.15%
lifesciences patent system

ReShape Lifesciences® Provides Update on 2024 Cost Reduction Plan and Reorganization to Prioritize Commercialization of Lap-Band® 2.0 FLEX
Published: 2024-03-04 (Crawled : 13:30) - globenewswire.com
RSLS | $0.1707 15K

Manufacturing

| -7.99% | O: -6.9% H: 6.86% C: 1.24%
lifesciences update commercialization

ReShape Lifesciences® Announces First Surgeries Utilizing Next-Generation Lap-Band® 2.0 FLEX
Published: 2024-02-22 (Crawled : 13:30) - globenewswire.com
RSLS | $0.1707 15K

Manufacturing

| -4.02% | O: 0.18% H: 1.74% C: -4.55%
lifesciences first

ReShape Lifesciences® Conducts Bariatric Fellows Training for its Lap-Band® System, Highlighting the Next-Generation Lap-Band® 2.0 FLEX
Published: 2024-01-24 (Crawled : 13:30) - globenewswire.com
RSLS | $0.1707 15K

Manufacturing

| -27.93% | O: 0.63% H: 0.72% C: -5.77%
lifesciences

ReShape Lifesciences® Engages Maxim Group LLC To Identify Strategic M&A Partnership Alternatives
Published: 2023-12-20 (Crawled : 13:30) - globenewswire.com
RSLS | $0.1707 15K

Manufacturing

| -48.73% | O: 3.46% H: 11.18% C: -5.23%
lifesciences partnership group

ReShape Lifesciences® Receives FDA PMA Supplement Approval for its Next-Generation Lap-Band® 2.0 FLEX
Published: 2023-12-12 (Crawled : 21:00) - globenewswire.com
RSLS | $0.1707 15K

Manufacturing

| -36.25% | O: 59.44% H: 47.43% C: -3.95%
lifesciences fda approval

ReShape Lifesciences® Enters into Warrant Exercise Transaction for $1.2 Million in Gross Proceeds
Published: 2023-11-21 (Crawled : 13:00) - globenewswire.com
RSLS | $0.1707 15K

Manufacturing

| -30.47% | O: -6.61% H: 3.02% C: -3.63%
lifesciences

ReShape Lifesciences® Reports Third Quarter Ended September 30, 2023 Financial Results and 2024 Cost Reduction Plan
Published: 2023-11-08 (Crawled : 22:00) - globenewswire.com
RSLS | $0.1707 15K

Manufacturing

| -36.98% | O: -6.66% H: 5.49% C: -2.7%
lifesciences financial results

ReShape Lifesciences® to Announce Financial Results for the Third Quarter Ended September 30, 2023 and Provide Corporate Update
Published: 2023-11-06 (Crawled : 13:30) - globenewswire.com
RSLS | $0.1707 15K

Manufacturing

| -36.51% | O: -0.79% H: 0.8% C: -4.96%
lifesciences update financial results

ReShape Lifesciences® Announces Pricing of $3.0 Million Public Offering
Published: 2023-09-29 (Crawled : 16:00) - globenewswire.com
RSLS | $0.1707 15K

Manufacturing